Arginase and C-reactive protein as potential serum-based biomarker of head and neck squamous cell carcinoma patients of north east India

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 6739-6748

  Choudhury, Biswadeep ^a,b   Srivastava, Shilpee ^a   Choudhury, Haider H ^a   Purkayastha, Alokananda ^b   DuttaGupta, Sumita ^a,b   Ghosh, Sankar Kumar ^a  

^a ASSAM UNIVERSITY   (India)

^b SILCHAR MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Arginase; Biochemical analytes; Catalase; CRP; HNSCC; LDH; OAT

Indexed keywords

AMYLASE; ARGINASE; C REACTIVE PROTEIN; CATALASE; LACTATE DEHYDROGENASE; ORNITHINE OXOACID AMINOTRANSFERASE;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; INDIA; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AMYLASES; ARGINASE; C-REACTIVE PROTEIN; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INDIA; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904986672     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1851-y     Document Type: Article

References (79)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 1993;54:594-606. (Pubitemid 23188190)
2. Silveira NJ, Varuzza L, Machado-Lima A, et al. Searching for molecular markers in head and neck squamous cell carcinomas (HNSC C) by statistical and bioinformatic analysis of larynx-derived SAGE libraries. BMC Med Genom. 2008;1:56.
3. Hartwell L, Mankoff D, Paulovich A, Ramsey S, Swisher E. Cancer biomarkers: a systems approach. Nature Biotech. 2006;24:905-8. (Pubitemid 44215377)
4. Nicolini A, Tartarelli G, Carpi A, et al. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer. 2006;6:269.
5. Mondal R, Ghosh SK, Talukdar FR, Laskar RS. Association of mitochondrial D-loop mutations with GSTM1 and GSTT1 polymorphisms in oral carcinoma: a case control study from Northeast India. Oral Oncol. 2013;49:345-53.
6. Mondal R, Ghosh SK. Accumulation of mutations over the complete mitochondrial genome in tobacco-related oral cancer from northeast India. Mito DNA. 2013;24:432-9.
7. Mondal R, Ghosh SK, Choudhury JH, et al. Mitochondrial DNA copy number and risk of oral cancer: a report from Northeast India. PloS One. 2013;8:e57771.
8. de Boniface J, Mao Y, Schmidt-Mende J, Kiessling R, Poschke I. Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients. Oncoimmunol. 2012;1:1305-12.
9. Perez G, Olivares IM, Rodriguez MG, Ceballos GM, Garcia Sanchez JR. Arginase activity in patients with breast cancer: an analysis of plasma, tumors, and its relationship with the presence of the estrogen receptor. Onkologie. 2012;35:570-4.
10. Mumenthaler SM, Yu H, Tze S, et al. Expression of arginase II in prostate cancer. Int J Oncol. 2008;32:357-65. (Pubitemid 351188302)
11. Wu CW, Chung WW, Chi CW, et al. Immunohistochemical study of arginase in cancer of the stomach. Virchows Arch. 1996;428:325-31.
12. Grabon W, Mielczarek-Puta M, Chrzanowska A, Baranczyk-Kuzma A. L-arginine as a factor increasing arginase significance in diagnosis of primary and metastatic colorectal cancer. Clin Biochem. 2009;42:353-7.
13. Zhou D, Cheng X, Yang S, et al. Expression and bioinformatic analysis of ornithine aminotransferase in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2012;15:521-30.
14. Matthaei KI, Williams JF. Ornithine aminotransferase turnover in host tissues of tumor-bearing rats. J Natl Cancer Inst. 1987;79:805-9. (Pubitemid 17145703)
15. Glorieux C, Dejeans N, Sid B, Beck R, Calderon PB, Verrax J. Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy. Biochem Pharmacol. 2011;82:1384-90.
16. Sullivan NJ, Tober KL, Burns EM, et al. UV light B-mediated inhibition of skin catalase activity promotes Gr-1+ CD11b+ myeloid cell expansion. J Invest Dermatol. 2012;132:695-702.
17. de Oliveira HC, Miranda-Vilela AL, Rocha DM, de Oliveira SF, Hatagima A, de Nazare Klautau-Guimaraes M. Superoxide dismutase, catalase, glutathione peroxidase and gluthatione S-transferases M1 and T1 gene polymorphisms in three Brazilian population groups. Genet Mol Biol. 2011;34:11-8.
18. Goh J, Enns L, Fatemie S, et al. Mitochondrial targeted catalase suppresses invasive breast cancer in mice. BMC Cancer. 2011;11:191.
19. Glick Jr JH. Serum lactate dehydrogenase isoenzyme and total lactate dehydrogenase values in health and disease, and clinical evaluation of these tests by means of discriminant analysis. Am J Clin Pathol. 1969;52:320-8.
20. Koukourakis MI, Giatromanolaki A, Winter S, Leek R, Sivridis E, Harris AL. Lactate dehydrogenase 5 expression in squamous cell head and neck cancer relates to prognosis following radical or post-operative radiotherapy. Oncol. 2009;77:285-92.
21. Koukourakis M, Giatromanolaki A, Sivridis E. Colorectal cancer: lactate dehydrogenase (LDH) Activity as a prognostic marker. In: Hayat MA, editor. Colorectal Cancer. Netherlands: Springer; 2009. p. 241-53.
22. Takeuchi T, Fujiki H, Kameya T. Characterization of amylases produced by tumors. Clin Chem. 1981;27:556-9. (Pubitemid 11109749)
23. Schlikker I, Nakad A, Gerbaux A, et al. Hyperamylasemia with papillary serous cystadenocarcinoma of the ovary. Acta Clin Belg. 1989;44:255-8.
24. Chen IW, Kereiakes JG, Silberstein EB, Aron BS, Saenger EL. Radiation-induced change in serum and urinary amylase levels in man. Rad Res. 1973;54:141-51.
25. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805-12. (Pubitemid 38057722)
26. Khandavilli SD, Ceallaigh PO, Lloyd CJ, Whitaker R. Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol. 2009;45:912-4.
27. Chang PY, Kuo YB, Wu TL, et al. Association and prognostic value of serum inflammation markers in patients with leukoplakia and oral cavity cancer. Clin Chem Lab Med. 2013;51(6):1291-300.
28. Chen HH, Chen IH, Liao CT, Wei FC, Lee LY, Huang SF. Preoperative circulating C-reactive protein levels predict pathological aggressiveness in oral squamous cell carcinoma: a retrospective clinical study. Clin Otolaryngol. 2011;36:147-53.
29. Narang AP, Greval RS, Chopra H, Kalra CS. The role of two enzymes (LDH and PHI) and a tumour marker (CEA) in the prognostic evalution of head and neck malignancy. Ind J Otolaryngol Head Neck Surg. 2001;53:76-80.
30. Kim HR, Rho HW, Park JW, Park BH, Kim JS, Lee MW. Assay of ornithine aminotransferase with ninhydrin. Analyt Biochem. 1994;223:205-7. (Pubitemid 124007178)
31. Aebi H, Suter H, Feinstein RN. Activity and stability of catalase in blood and tissues of normal and acatalasemic mice. Biochem Genet. 1968;2:245-51.
32. Lorentz K, Gutschow B, Renner F. Evaluation of a direct alpha-amylase assay using 2-chloro-4-nitrophenyl-alpha-D-maltotrioside. Clin Chem Lab Med. 1999;37:1053-62. (Pubitemid 30103262)
33. Horder M, Gerhardt W. The Scandinavian Committee on Enzymes (SCE). Scand J Clin Lab Invest Suppl. 1985;179:13-7. (Pubitemid 16225301)
34. Otsuji S, Shibata H, Umeda M. Turbidimetric immunoassay of serum C-reactive protein. Clin Chem. 1982;28:2121-4. (Pubitemid 12034063)
35. Nair U, Bartsch H, Nair J. Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms. Mutagen. 2004;19:251-62. (Pubitemid 39028948)
36. Maruyama H, Yasui T, Ishikawa-Fujiwara T, Morii E, Yamamoto Y, Yoshii T, Takenaka Y, Nakahara S, Todo T, Hongyo T, Inohara H. Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population. Cancer Science 2014:n/a-n/a.
37. Mondal R, Ghosh SK. Hpv infection, gstm1-gstt1 genotypes, mitochondrial mutations and tobacco association with oral cancer from northeast India. Head & Neck Oncology. 2013;5:46.
38. Nagpal JK, Patnaik S, Das BR. Prevalence of high-risk human papilloma virus types and its association with p53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of eastern India. Int J Cancer. 2002;97:649-53. (Pubitemid 34087805)
39. Feun L, You M, Wu CJ, et al. Arginine deprivation as a targeted therapy for cancer. Curr Pharma Design. 2008;14:1049-57. (Pubitemid 351982554)
40. Srivastava S, Ghosh SK. Arginine metabolism: role and significance in cancer. Tissue Sc Eng. 2013;S6:2157-7552.
41. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269-74. (Pubitemid 37279849)
42. Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J, et al. Stat3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest. 2013;123:1580-9.
43. Liu C-Y, Wang Y-M, Wang C-L, Feng P-H, Ko H-W, Liu Y-H, et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed cd11b+/cd14-/cd15+/cd33+ myeloid-derived suppressor cells and cd8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Can Res Clin Oncol. 2010;136:35-45.
44. Munder M. Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol. 2009;158:638-51.
45. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904-12.
46. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion. Can Res. 2005;65:3044-8. (Pubitemid 40524582)
47. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Can Res. 2009;69:1553-60.
48. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Can Res. 2007;13:721s-6s.
49. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-7. (Pubitemid 36019639)
50. Kruse AL, Luebbers HT, Gratz KW. C-reactive protein levels: a prognostic marker for patients with head and neck cancer? Head Neck Oncol. 2010;2:21.
51. Peter F, Wittekindt C, Finkensieper M, Kiehntopf M, Guntinas-Lichius O. Prognostic impact of pretherapeutic laboratory values in head and neck cancer patients. J Cancer Res Clin Oncol. 2013;139:171-8.
52. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291:585-90. (Pubitemid 38500312)
53. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res. 2006;66:2483-7.
54. Kwon KA, Kim SH, Oh SY, et al. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer. 2010;10:203.
55. Shiu YC, Lin JK, Huang CJ, et al. Is C-reactive protein a prognostic factor of colorectal cancer? Dis Col Rect. 2008;51:443-9.
56. Prizment AE, Folsom AR, Dreyfus J, et al. Plasma C-reactive protein, genetic risk score, and risk of common cancers in the Atherosclerosis Risk in Communities study. Cancer Causes Control. 2013;24(12):2077-87.
57. Chaturvedi AK, Caporaso NE, Katki HA, et al. C-reactive protein and risk of lung cancer. J Clin Oncol. 2010;28:2719-26.
58. Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Int Med. 2005;142:425-32.
59. Gockel I, Dirksen K, Messow CM, Junginger T. Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol. 2006;12:3746-50. (Pubitemid 43950953)
60. Nozoe T, Saeki H, Ohga T, Sugimachi K. Clinicopathological features of early esophageal squamous cell carcinoma with subsequent recurrence. Dis Esophagus. 2002;15:145-8. (Pubitemid 35264637)
61. Zingg U, Forberger J, Rajcic B, Langton C, Jamieson GG. Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer. J Gastroint Surg. 2010;14:462-9.
62. Chen HH, Wang HM, Fan KH, Lin CY, Yen TC, Liao CT, et al. Pretreatment levels of c-reactive protein and squamous cell carcinoma antigen for predicting the aggressiveness of pharyngolaryngeal carcinoma. PloS ONE. 2013;8:31.
63. Allin KH, Bojesen SE, Nordestgaard BG. Baseline c-reactive protein is associated with incident cancer and survival in patientswith cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:2217-24.
64. Allin KH, Nordestgaard BG. Elevated c-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48:155-70.
65. Coventry B, Ashdown M, Quinn M, Markovic S, Yatomi-Clarke S, Robinson A. CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Transl Med. 2009;7:102.
66. Mikirova N, Casciari J, Rogers A, Taylor P. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med. 2012;10:189.
67. Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 2006;94:1568-71. (Pubitemid 43924914)
68. Wang F, Arun P, Friedman J, Chen Z, Van Waes C. Current and potential inflammation targeted therapies in head and neck cancer. Curr Opin Pharmacol. 2009;9:389-95.
69. Hall WA, Nickleach DC, Master VA, Prabhu RS, Rossi PJ, Godette K, et al. The association between c-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate. Cancer. 2013;119:3272-9.
70. Zeng YC, Xue M, Chi F, Xu ZG, Fan GL, Wu R, et al. C-reactive protein level predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treatedwith chemoradiotherapy. Tumour Biol. 2012;33:891-5.
71. Pongrakhananon V, Nimmannit U, Luanpitpong S, Rojanasakul Y, Chanvorachote P. Curcumin sensitizes non-small cell lung cancer cell anoikis through reactive oxygen species-mediated Bcl-2 downregulation. Apoptosis. 2010;15:574-85.
72. Rungtabnapa P, Nimmannit U, Halim H, Rojanasakul Y, Chanvorachote P. Hydrogen peroxide inhibits non-small cell lung cancer cell anoikis through the inhibition of caveolin-1 degradation. Am J Physiol Cell Physiol. 2011;300:C235-45.
73. Davison CA, Durbin SM, Thau MR, et al. Antioxidant enzymes mediate survival of breast cancer cells deprived of extracellular matrix. Cancer Res. 2013;73:3704-15.
74. Shi DY, Xie FZ, Zhai C, Stern JS, Liu Y, Liu SL. The role of cellular oxidative stress in regulating glycolysis energy metabolism in hepatoma cells. Mol Cancer. 2009;8:32.
75. Montalban C, Abraira V, Arcaini L, et al. Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. Br H Haematol. 2012;159:164-71.
76. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol. 2009;92:329-33.
77. Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol. 2012;30:3402-7.
78. Fan J, Hitosugi T, Chung TW, et al. Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD (+) redox homeostasis in cancer cells. Mol Cell Biol. 2011;31:4938-50.
79. Wan XB, Wei L, Li H, et al. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma. Eur J Cancer. 2013;49:2356-64.